Last Updated: September 24, 2026

Patent: 9,879,063

✉ Email this page to a colleague

Summary for Patent: 9,879,063

Title:	Engineered polypeptides having enhanced duration of action and reduced immunogenicity
Abstract:	Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
Inventor(s):	Mary Erickson, David C. LITZINGER, Soumitra S. Ghosh, Zijian Guo, Caroline Ekblad, Jonathan D. Roth
Assignee:	Novelion Therapeutics Inc , Amryt Pharmaceuticals Inc
Application Number:	US14/837,705
Patent Claims:	see list of patent claims

Details for Patent 9,879,063

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	24-Feb-14	⤷ Start Trial	2035-08-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,879,063

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
China	103957926	⤷ Start Trial
Cyprus	1121780	⤷ Start Trial
Denmark	2729160	⤷ Start Trial
European Patent Office	2729160	⤷ Start Trial
Spain	2732475	⤷ Start Trial
Japan	2014528917	⤷ Start Trial
Japan	2016183180	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.